US FDA Guidance On Interference With Inspections Needs More Detail, Attorneys Say
Agency should clarify how quickly it expects requested documents to be produced before a company is determined to have delayed an inspection, attorneys say during a FDLI meeting discussion of how a 2012 law enabling the agency to put a foreign facility on import alert for delaying, limiting, or refusing an inspection has played out.
You may also be interested in...
FDA warning letter says Shandong Vianor Biotech in China falsified test results and barred an investigator from entering a laboratory during an inspection of the firm’s facility in May.
A review of recent US FDA citations has industry concerned about the extent to which agency investigators may be reviewing security video archives as part of their pharmaceutical manufacturing plant inspections.
FDA tweaks final guidance on what constitutes interference with FDA inspections to include examples of ‘reasonable’ explanations for sponsor delays; industry had requested many other changes.